Cervical Neoplasms Clinical Trial
Official title:
Phase II Clinical Trial for Adjuvant Concurrent Chemoradiation Therapy in Post-operative Cervical Cancer Patients
The standard postoperative treatment for patients with cervical cancer who had high-risk factors is chemoradiation. Generally, weekly cisplatin or 5FU+cisplatin every 3 week have been used as chemotherapy regimens of chemoradiation. Based on their experience, the investigators hypothesized that tri-weekly cisplatin could be superior to weekly cisplatin. Therefore, the investigators are going to perform the efficacy study of postoperative, tri-weekly cisplatin chemoradiation for patients with cervical cancer.
Cervical carcinoma is one of the most common gynecologic cancers worldwide. The prognosis of
cervical cancer is favorable, with around 80-90% 5-year survival rate in early stage disease.
However, advanced disease carries a poor prognosis.
The standard postoperative treatment for patients with cervical cancer who had high-risk
factors is chemoradiation. Based on the results of five randomized clinical trials, which
consistently showed improved survival in patients treated with cisplatin-based CRT, the
National Cancer Institute (NCI) of the United States announced that 'Strong consideration
should be given to the incorporation of concurrent cisplatin-based chemotherapy with RT in
women who require radiation therapy for treatment of cervical cancer' in 1999.
Although recently reported meta-analysis studies also demonstrated improved local control
rates and survival with cisplatin-based chemotherapy concurrent to radiation therapy (RT),
the optimal cisplatin dose and dosing schedule are still undetermined. Among the previous
five randomized clinical trials, two trials performed by the Gynecologic Oncology Group (GOG)
used weekly cisplatin 40 mg/m2 while the other three trials used tri-weekly cisplatin at a
dosage range of 50 mg/m2 to 75 mg/m2 combined with 5-fluorouracil (5-FU).
Despite the diversity in cisplatin dose and dosing schedules, weekly cisplatin at a dose of
40 mg/m2 concurrent to RT is widely accepted as the standard regimen of CRT because of its
convenience, equal effectiveness, and favorable toxicity in comparison to other 5-FU combined
regimens.
However, as a result of the GOG 165 study, which was closed prematurely because an interim
analysis found that patients in the 5-FU treatment group were not likely to achieve a better
outcome, the role of 5-FU (previously popularly included in clinical trials) as a
radiosensitizer became subject to debate. Furthermore, a clinical trial performed by the NCI
in Canada comparing pelvic RT alone with weekly cisplatin 40 mg/m2 concurrent to RT failed to
show improvement of progression free and 5-year survival. While the authors suggested several
possible reasons for why their study failed to demonstrate a survival benefit with concurrent
weekly cisplatin 40 mg/m2 chemotherapy, other investigators have tried to find another
optimal dose and dosing schedule for cisplatin administration.
In light of the results of the previous clinical trial that indicated 5-FU may not be an
active radiosensitizer, weekly cisplatin 40 mg/m2 and tri-weekly cisplatin 75 mg/m2 remain
the most popular cisplatin doses and dosing schedules. However, despite the possible
advantages of tri-weekly cisplatin 75 mg/m2, which offer an increased peak concentration of
cisplatin and cisplatin administration during brachytherapy, no clinical trials have efficacy
of tri-weekly cisplatin-based chemotherapy concurrent to RT.
Therefore, the investigators are going to perform the efficacy study of postoperative,
tri-weekly cisplatin chemoradiation for patients with cervical cancer.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02267876 -
Longitudinal Clinical Evaluation of the HPV Assay on the BD VIPER LT System With Cervical Specimens
|
||
Enrolling by invitation |
NCT04266093 -
Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies
|
||
Completed |
NCT00916500 -
Concurrent Chemoradiation With Cisplatin Every 3 Week in Advanced Cervical Cancer
|
Phase 2 | |
Completed |
NCT01627288 -
Integrated Dose Escalation for Advanced, Localized Gynecologic Cancer (The IDEAL - GYN Trial)
|
N/A | |
Not yet recruiting |
NCT05824494 -
Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors
|
Phase 2 | |
Recruiting |
NCT04096911 -
Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical Cancer
|
Phase 2 | |
Terminated |
NCT00190528 -
A Trial of Neoadjuvant Chemotherapy + Surgery vs. Surgery for Bulky Stage I/II Cervical Cancer
|
Phase 3 |